vimarsana.com
Home
Live Updates
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment ... : vimarsana.com
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment ...
ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today
Related Keywords
Washington
,
United States
,
Russia
,
Ukraine
,
Switzerland
,
Israel
,
Canada
,
United Kingdom
,
American
,
Peng Lu
,
Joan Mendivil
,
Marca Riedl
,
American Academy Of Allergy
,
European Union
,
Waltere Washington Convention Center
,
Wave Ii Disease Specific Program
,
Exchange Commission
,
American Academy
,
Scientific Meeting
,
Clinical Immunology
,
Oral Deucrictibant
,
Hereditary Angioedema Attacks
,
Chief Medical Officer
,
Treat All
,
Patient Satisfaction
,
On Demand Treatment
,
Specific Program
,
Statement Regarding Forward Looking
,
Annual Report
,
Maggie Beller Executive Director
,
Region
,
vimarsana.com © 2020. All Rights Reserved.